PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
11454254-3	2001	The thienopyridines, ticlopidine and clopidogrel, act, via metabolites, on the platelet ADP receptor subtype now designated P2Y(12 )(formerly P(2T), P2T (AC), P2Y (ADP) or P2Y(cyc)) and these agents have proven clinical efficacy.	Thienopyridines	4-19	purinergic receptor P2Y12	Homo sapiens	159-168
14717977-1	2004	The P2Y12 ADP receptor is one of the major regulators of platelet activation and the target of antithrombotic thienopyridines (ticlopidine and clopidogrel).	Thienopyridines	110-125	purinergic receptor P2Y12	Homo sapiens	4-9
14684289-1	2004	Novel classes of thienopyrimidines and thienopyridines have been identified as potent inhibitors of VEGFR-2 kinase.	Thienopyridines	39-54	kinase insert domain receptor	Homo sapiens	100-107
14610915-4	2003	P2Y12 inhibits adenylyl cyclase through a glycoprotein i (Gi)-dependent pathway, and is the target of the clinically used thienopyridines, ticlopidine (Ticlid, F. Hoffman-La Roche) and clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Synthelabo).	Thienopyridines	122-137	purinergic receptor P2Y12	Homo sapiens	0-5
11454254-3	2001	The thienopyridines, ticlopidine and clopidogrel, act, via metabolites, on the platelet ADP receptor subtype now designated P2Y(12 )(formerly P(2T), P2T (AC), P2Y (ADP) or P2Y(cyc)) and these agents have proven clinical efficacy.	Thienopyridines	4-19	purinergic receptor P2Y12	Homo sapiens	172-180
31590445-7	2019	We used this assay to characterize a series of thienopyridines with in vitro bone anabolic activity, one of which was identified as a selective CDK8/19 inhibitor.	Thienopyridines	47-62	cyclin dependent kinase 8	Homo sapiens	144-151
11192941-1	2000	We propose that anti-platelet thienopyridines, such as ticlopidine or clopidogrel, are thrombolytic owing to endothelial release of prostacyclin (PGI2) and tissue plasminogen activator (t-PA).	Thienopyridines	30-45	plasminogen activator, tissue type	Rattus norvegicus	156-190
34731765-3	2022	Despite that P2Y12 platelets" receptor is an excellent target for developing antiplatelet agents, only five approved medications are currently in clinical use which are classified into thienopyridines and nucleoside-nucleotide derivatives.	Thienopyridines	185-200	purinergic receptor P2Y12	Homo sapiens	13-18
33335655-0	2020	Novel Thienopyridines as RIPK2 Inhibitors for Treating Inflammatory Bowel Disease.	Thienopyridines	6-21	receptor interacting serine/threonine kinase 2	Homo sapiens	25-30
31590445-8	2019	Thienopyridines inhibited luciferase induction in the WT but not dKO cells and their IC50 values in the WT reporter assay showed near-perfect correlation (R2 = 0.98) with their reported activities in a bone anabolic activity assay, confirming that the latter function is mediated by CDK8/19 and validating our assay as a robust and quantitative method for CDK8/19 inhibition.	Thienopyridines	0-15	cyclin dependent kinase 8	Homo sapiens	356-363
31590445-8	2019	Thienopyridines inhibited luciferase induction in the WT but not dKO cells and their IC50 values in the WT reporter assay showed near-perfect correlation (R2 = 0.98) with their reported activities in a bone anabolic activity assay, confirming that the latter function is mediated by CDK8/19 and validating our assay as a robust and quantitative method for CDK8/19 inhibition.	Thienopyridines	0-15	cyclin dependent kinase 8	Homo sapiens	283-290
27548273-8	2017	Patients discharged with ticagrelor versus thienopyridines demonstrated a higher rate of crossover to other P2Y12 inhibitors (11 vs. 5%, p = 0.03).	Thienopyridines	43-58	purinergic receptor P2Y12	Homo sapiens	108-113
29710801-1	2018	The thienopyridines class of drugs used as P2Y12 receptor antagonists plays a vital role in antiplatelet therapy.	Thienopyridines	4-19	purinergic receptor P2Y12	Rattus norvegicus	43-48
25443875-3	2014	We hypothesised that thienopyridines expose the free thiol group once acidified (by the stomach) before biotransformation into active metabolites, and in the presence of nitrite (from saliva and the stomach) to form nitrosothiol derivatives (Thienopyridine induced-SNO formation).	Thienopyridines	21-36	strawberry notch homolog 1	Homo sapiens	265-268
26758983-3	2016	P2Y12 receptor antagonists, thienopyridines and ticagrelor, differ in their mode of action being prodrugs instead of direct acting and irreversibly instead of reversibly binding to P2Y12 .	Thienopyridines	28-43	purinergic receptor P2Y12	Homo sapiens	0-5
26758983-3	2016	P2Y12 receptor antagonists, thienopyridines and ticagrelor, differ in their mode of action being prodrugs instead of direct acting and irreversibly instead of reversibly binding to P2Y12 .	Thienopyridines	28-43	purinergic receptor P2Y12	Homo sapiens	181-186
26270719-2	2016	As cangrelor is administered intravenously, it is necessary to switch to an oral P2Y12 antagonist following PCI, such as the thienopyridines clopidogrel, and prasugrel or the non-pyridine ticagrelor.	Thienopyridines	125-140	purinergic receptor P2Y12	Homo sapiens	81-86
26444255-5	2016	Cangrelor blocks the binding to the platelet P2Y12 receptor of the active metabolite of the thienopyridines, clopidogrel and prasugrel.	Thienopyridines	92-107	purinergic receptor P2Y12	Homo sapiens	45-50
25443875-4	2014	We have performed in vitro studies with each of the thienopyridines tablets/compounds confirming direct Th-SNO formation from the parent (inactive) drug by the following mechanism.	Thienopyridines	52-67	strawberry notch homolog 1	Homo sapiens	107-110
24142066-1	2014	Thienopyridines are a class of antiplatelet drugs that are metabolized in the liver to several metabolites, of which only one active metabolite can irreversibly antagonize the platelet P2Y12 receptor.	Thienopyridines	0-15	purinergic receptor P2Y, G-protein coupled 12	Mus musculus	185-190
24845219-3	2014	Considering the importance of P2Y12 receptor in platelet function, a class of antiplatelet drugs, thienopyridines, have been designed and successfully used to prevent thrombosis.	Thienopyridines	98-113	purinergic receptor P2Y12	Homo sapiens	30-35
24845219-8	2014	P2Y12 receptor may also be expressed in other cells of the immune system, indicating that thienopyridines could directly influence the immune system rather than only through platelets.	Thienopyridines	90-105	purinergic receptor P2Y12	Homo sapiens	0-5
23476040-0	2013	Impaired platelet P2Y12 inhibition by thienopyridines in chronic kidney disease: mechanisms, clinical relevance and pharmacological options.	Thienopyridines	38-53	purinergic receptor P2Y12	Homo sapiens	18-23
23925438-8	2013	In conclusion, ELISA-VASP is a fast, easy-to-use and specific test to identify HPR in ACS patients on thienopyridines.	Thienopyridines	102-117	vasodilator stimulated phosphoprotein	Homo sapiens	21-25
25163670-4	2014	Thienopyridines are class of drugs that specifically and irreversibly inhibit the P2Y12 receptor.	Thienopyridines	0-15	purinergic receptor P2Y12	Homo sapiens	82-87
22963529-2	2013	The first family of adenosine diphosphate P2Y12 receptors inhibiting drug is represented by thienopyridines and among these ticlopidine was the first approved by Food and Drug Administration; actually its use is discouraged because of its potential side effects (neutropenia, anemia, gastrointestinal distress and thrombotic thrombocytopenic purpura).	Thienopyridines	92-107	purinergic receptor P2Y12	Homo sapiens	42-47
23816027-2	2013	BACKGROUND: It has been suggested that LTA and VASP-P assay correlate differently according to the level of P2Y12 receptor blockade by thienopyridines.	Thienopyridines	135-150	vasodilator stimulated phosphoprotein	Homo sapiens	47-51
23816027-2	2013	BACKGROUND: It has been suggested that LTA and VASP-P assay correlate differently according to the level of P2Y12 receptor blockade by thienopyridines.	Thienopyridines	135-150	purinergic receptor P2Y12	Homo sapiens	108-113
21946108-1	2011	Thienopyridines (ticlopidine, clopidogrel and prasugrel) are pro-drugs that require metabolism to exhibit a critical thiol group in the active form that binds to the P2Y12 receptor to inhibit platelet activation and prevent thrombus formation in vivo.	Thienopyridines	0-15	purinergic receptor P2Y12	Homo sapiens	166-171
23617077-0	2013	A QSAR and molecular modeling study on a series of 3, 4-dihydro-1-isoquinolinamines and thienopyridines acting as nitric oxide synthase inhibitors.	Thienopyridines	88-103	nitric oxide synthase 1	Homo sapiens	114-135
22974536-1	2012	BACKGROUND: A recent clinical trial has demonstrated that patients with acute coronary syndromes (ACS) and the reduced function allele CYP2C19*2 (*2 allele), who are treated with thienopyridines, have an increased risk of adverse cardiac events with clopidogrel, but not with prasugrel.	Thienopyridines	179-194	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	135-142
22918731-2	2012	Among the P2Y12 receptor inhibitors, the group of thienopyridines include ticlopidine, clopidogrel and prasugrel, all of which are orally administered prodrugs leading to irreversible P2Y12 receptor inhibition.	Thienopyridines	50-65	purinergic receptor P2Y12	Homo sapiens	10-15
22918731-2	2012	Among the P2Y12 receptor inhibitors, the group of thienopyridines include ticlopidine, clopidogrel and prasugrel, all of which are orally administered prodrugs leading to irreversible P2Y12 receptor inhibition.	Thienopyridines	50-65	purinergic receptor P2Y12	Homo sapiens	184-189
21822146-7	2011	Clopidogrel-chloride-SNO displayed rapid-release kinetics in a chemical environment, which was reflected by immediate and transient vasorelaxation when compared with the SNO derivatives of the other thienopyridines.	Thienopyridines	199-214	strawberry notch homolog 1	Homo sapiens	21-24
21822146-10	2011	Differences in SNO yield and vasoactivity exist between thienopyridine preparations that might be important to our understanding of the direct pharmacological effectiveness of thienopyridines on vascular and platelet function.	Thienopyridines	176-191	strawberry notch homolog 1	Homo sapiens	15-18
21828263-6	2011	These studies show that, in vitro, CYP3A4/5, 2C19, and 2B6 are individually capable of converting clopidogrel and prasugrel to the AM and that the cytochrome P450 preference for these two thienopyridines is very similar.	Thienopyridines	188-203	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	35-49
21826477-2	2011	The available thienopyridines are prodrugs and must be converted into active forms by the cytochrome P450 (CYP) enzyme system.	Thienopyridines	14-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-105
21826477-2	2011	The available thienopyridines are prodrugs and must be converted into active forms by the cytochrome P450 (CYP) enzyme system.	Thienopyridines	14-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-110
21074424-0	2010	Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors.	Thienopyridines	29-44	checkpoint kinase 1	Homo sapiens	55-59
21447613-7	2011	In conclusion, the TI of thienopyridines in the mouse may be decreased by P2Y(12)-independent off-target effects at the vessel wall, whereas that of elinogrel may be enhanced by the reversible, competitive nature of the antiplatelet agent.	Thienopyridines	25-40	purinergic receptor P2Y, G-protein coupled 12	Mus musculus	74-81
20210760-3	2010	As a result, this receptor has been a target for the development of clinically effective antiplatelet agents, such as the thienopyridines ticlopidine and, more recently, clopidogrel, the only two currently FDA-approved P2Y12 antagonists.	Thienopyridines	122-137	purinergic receptor P2Y12	Homo sapiens	219-224
21073556-3	2010	Other interactions between thienopyridines and CYP3A4/5 have also been reported for statins and calcium channel blockers.	Thienopyridines	27-42	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	47-53
20977287-5	2010	On the other hand, thienopyridines suppress the platelet aggregation adenosine diphosphate (ADP) pathway by inhibiting the platelet P2Y12 subtype of the ADP receptor.	Thienopyridines	19-34	purinergic receptor P2Y12	Homo sapiens	132-137
19946242-3	2009	Thienopyridines are a class of drugs that function via inhibition of the adenosine diphosphate (ADP) P2Y12 platelet receptors.	Thienopyridines	0-15	purinergic receptor P2Y12	Homo sapiens	101-106
22282698-5	2010	Recent investigations have included ticagrelor, a reversible inhibitor of the P2Y12 platelet receptor, which appears to have overcome several drawbacks of the current thienopyridines.	Thienopyridines	167-182	purinergic receptor P2Y12	Homo sapiens	78-83
19882081-0	2009	P2Y12 inhibitors: thienopyridines and direct oral inhibitors.	Thienopyridines	18-33	purinergic receptor P2Y12	Homo sapiens	0-5
17635731-3	2007	In contrast to aspirin, studies that used specific tests to measure the pharmacological effect of thienopyridines [e.g. vasodilator-stimulated phosphoprotein (VASP)] showed a wide variability of responses to these drugs, with significant proportions of subjects (15-30%) who are very poor responders.	Thienopyridines	98-113	vasodilator stimulated phosphoprotein	Homo sapiens	120-157
19678800-0	2009	Platelet P2Y12 receptor inhibition by thienopyridines: status and future.	Thienopyridines	38-53	purinergic receptor P2Y12	Homo sapiens	9-14
17635731-3	2007	In contrast to aspirin, studies that used specific tests to measure the pharmacological effect of thienopyridines [e.g. vasodilator-stimulated phosphoprotein (VASP)] showed a wide variability of responses to these drugs, with significant proportions of subjects (15-30%) who are very poor responders.	Thienopyridines	98-113	vasodilator stimulated phosphoprotein	Homo sapiens	159-163
17234410-0	2007	Discovery of thienopyridines as Src-family selective Lck inhibitors.	Thienopyridines	13-28	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	53-56
17234410-0	2007	Discovery of thienopyridines as Src-family selective Lck inhibitors.	Thienopyridines	13-28	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	32-35
17580012-3	2007	STUDY SELECTION: We included randomized controlled trials that assessed the clinical efficacy (risk of death or infarction) and safety (bleeding and thrombocytopenia) of GPIIb/IIIa inhibitors in patients pretreated with thienopyridines.	Thienopyridines	220-235	integrin subunit alpha 2b	Homo sapiens	170-175
17580012-7	2007	CONCLUSIONS: Use of GPIIb/IIIa inhibitors reduces the risk of adverse cardiac events in NSTEACS patients pre-treated with aspirin and thienopyridines but increases the risk of severe bleeding and thrombocytopenia.	Thienopyridines	134-149	integrin subunit alpha 2b	Homo sapiens	20-25
17234410-2	2007	These thienopyridines were designed based on a desire to access the unique residues in the extended hinge region of Lck.	Thienopyridines	6-21	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	116-119
16194206-6	2005	Conversely, secreted ADP strongly potentiated Rac activation induced by FcgammaRIIa clustering or TRAP via its P2Y12 receptor, the target of antithrombotic thienopyridines.	Thienopyridines	156-171	AKT serine/threonine kinase 1	Homo sapiens	46-49
17187456-8	2007	Two direct and reversible P2Y12 antagonists, cangrelor and AZD6140, have very rapid onset and reversal of platelet inhibition, which make them attractive alternatives to thienopyridines, especially when rapid inhibition of platelet aggregation or its quick reversal are required.	Thienopyridines	170-185	purinergic receptor P2Y12	Homo sapiens	26-31
16941047-8	2006	Two direct and reversible P2Y(12) antagonists, cangrelor and AZD6140, feature very rapid onset and reversal of platelet inhibition, which make them attractive alternatives to thienopyridines, especially when rapid inhibition of platelet aggregation or its quick reversal are required.	Thienopyridines	175-190	purinergic receptor P2Y12	Homo sapiens	26-33
17066149-8	2006	Two direct and reversible P2Y12 antagonists, cangrelor and AZD6140, feature very rapid onset and reversal of platelet inhibition, which make them attractive alternatives to thienopyridines, especially when rapid inhibition of platelet aggregation or its quick reversal are required.	Thienopyridines	173-188	purinergic receptor P2Y12	Homo sapiens	26-31
16194206-6	2005	Conversely, secreted ADP strongly potentiated Rac activation induced by FcgammaRIIa clustering or TRAP via its P2Y12 receptor, the target of antithrombotic thienopyridines.	Thienopyridines	156-171	purinergic receptor P2Y12	Homo sapiens	111-116
15816504-4	2005	The thienopyridines (ticlopidine, clopidogrel and prasugrel) irreversibly inactivate the P2Y12 receptor via the covalent binding of an active metabolite generated in the liver, while the other compounds are competitive antagonists.	Thienopyridines	4-19	purinergic receptor P2Y, G-protein coupled 12	Mus musculus	89-94
16353041-16	2005	CONCLUSION: In pts with NSTEACS both thienopyridines attenuated acute phase elevation of vWF.	Thienopyridines	37-52	von Willebrand factor	Homo sapiens	89-92